Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 10, 2008
JNCI Journal of the National Cancer Institute 2008 100(12):842-844; doi:10.1093/jnci/djn197
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/12/842    most recent
djn197v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Better Prioritization May Speed Approval of Adjuvant Therapies in Breast Cancer

Rabiya S. Tuma

The first 150 words of the full text of this article appear below.

Improvements in detection and treatment have reduced the risk of relapse for women diagnosed with early-stage breast cancer over the last several decades. As a consequence of that success, clinical trials that aim to test new therapies in adjuvant breast cancer must include more patients and monitor them longer to detect meaningful differences. With some trials expanding to 10,000 patients, researchers are concerned that the system is at a breaking point and will not be able to test all the new agents in development—or at least not in a timely manner.

"I worry about it all the time," said Eric Winer, M.D., director of the breast oncology center at Dana-Farber Cancer Institute in Boston and cochair of the Cancer and Leukemia Group B breast cancer committee. "It takes too long. Herceptin was approved for metastatic breast cancer in 1998. It took us until 2005 before we had a result in . . . [Full Text of this Article]

Tempered Reaction

Neoadjuvant Trials

Better Coordination


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?